Biologics have transformed treatment for life-threatening diseases and benefited millions of patients – but remain out of reach for too many other patients around the world. Ten years after the first biosimilar medicine was approved, competition from these products has driven increased access and healthcare system savings.
Genmab in HIV antibody deal
Latest NewsDanish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.
Fulfilling the Promise of Biosimilars
OpinionBiologics have transformed treatment for life-threatening diseases and benefited millions of patients – but remain out of reach for too many other patients around the world. Ten years after the first biosimilar medicine was approved, competition from these products has driven increased access and healthcare system savings.
Eppendorf – BioBLU® c Single-Use Vessels
ProductsEppendorf BioBLU Single-Use Vessels combine all the advantages of single-use technology with the trusted performance and scalability of a stirred-tank design.
Ploughing ahead after Phase III setback
Latest NewsHungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
Alzheimer’s vaccine clears Phase I
Latest NewsAraclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
EMA keeps approval speedway open
Latest NewsAfter a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to explore the concept further and will continue to accept proposals.
Dab hand at finances
AppointmentsUS- and UK-based genomics company Inivata has appointed Timothy Shannon as Chief Financial Officer. Shannon joins Inivata fom Baxano Surgical, where he held the position of CFO and treasurer.
Keeping an eye on monitoring
AppointmentsPhilippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.
Inflammation spin-off launched
Latest NewsLife science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
GSK picks up asthma mAb
Latest NewsGlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.